How AI is Driving the Future of Life Sciences Markets
Life sciences companies are using AI to speed up drug discovery, accelerate commercialization timelines, and improve back-office functions. The strong AI market in the U.S. has allowed for collaborations between AI-focused tech companies, life sciences companies, and universities. However, limitations around centralized data availability have made for challenges with deploying technology for clinical and commercial purposes. Europe has unique advantages due to many countries having centralized health data stores, collaborative networks, and strong public funding for research. As we have seen increased investment for companies utilizing AI to improve patient outcomes, life sciences companies who can unlock cross-border collaborations in the AI space may have an edge to tap into capital markets.
Join us for an insightful conversation with distinguished experts. The discussion will explore topics such as:
1. Market Landscape Comparison
• US Market
The U.S. currently dominates the AI in life sciences market, benefiting from deep venture capital pools, strong tech-biotech partnerships, and supportive regulatory engagement, especially from the FDA. North America captured about 48–52% of global revenue in 2025. Robust startup ecosystems and NIH research grants further fuel innovation, particularly in drug discovery and clinical AI tools.
> Size, investment flows, venture capital dominance
> Role of private sector and large pharma/biotech hubs (Boston, San Francisco)
• EU Market
Europe holds roughly 25–30% of the global AI life sciences market, with Germany, the UK, and France driving most regional demand. Regulatory initiatives, such as EU research funding and federated data systems, are accelerating adoption, even as evolving rules aim to balance innovation with safety and ethics
> Diversity across member states, strong public funding, and collaborative research networks
> Key hubs (Basel, Munich, Cambridge UK, Paris)
Contrast: Speed of innovation vs. regulatory complexity; fragmented vs. centralized approaches.
2. Regulatory Frameworks
Regulatory frameworks (like FDA’s AI-related programs) are increasingly incorporating AI decision-support into approval pathways, signalling a supportive climate; The EU’s AI Act and related federated data initiatives aim to ensure trustworthy, transparent AI deployment, balancing innovation with privacy and safety.
• US: FDA pathways (accelerated approvals, breakthrough designations)
• EU: EMA, MDR/IVDR reforms, country-level variations
• How regulatory differences affect market entry, clinical trials, and patient access
• Future Outlook: EU reforms (2024–2025 MDR/IVDR updates) vs. US FDA modernization.
3. Innovation & R&D Ecosystems & Cross Industry Partnerships
• Role of universities, research institutes, and public-private partnerships
• Cross-industry collaborations — between tech companies, biotech firms, and pharmaceutical giants — are becoming more common, accelerating innovation and commercialization
• Emerging technologies: AI in drug discovery, personalized medicine, digital health
• Funding models: NIH vs Horizon Europe.
Contrast: US dominance in biotech startups vs EU strength in collaborative research.
4. Collaboration Opportunities
• Joint clinical trials and harmonization of standards
• Data sharing and interoperability (GDPR vs HIPAA challenges)
• Cross-border investment and venture capital flows
• Talent mobility and workforce development
• Case studies of successful US–EU partnerships.
5. Challenges & Barriers
• Regulatory divergence and compliance costs
• Intellectual property and data protection differences
• Market fragmentation in the EU vs centralized US system
• Political and trade dynamics affecting collaboration.
6. Future Outlook & Strategic Recommendations
• How AI, genomics, and digital health could reshape collaboration
• Policy recommendations for smoother transatlantic cooperation
• Opportunities for SMEs and startups to benefit from joint initiatives
• Vision for a “Transatlantic Life Sciences Corridor”
SPEAKERS:
• Celia Beline, CEO, CILCARE
• Amanda Laskey, Life Sciences Senior Analyst, RSM US
• Dmitry Rakovitsky, Founder & CEO, ROKO LABS
• Frédéric Rossi, Regional Director – North America, BUSINESS FRANCE [Moderator]
TIME:
8:30 – 9:00 AM Check-in
9:00 – 10:15 AM Discussion
10:15 – 10:30 AM Networking